1808 related articles for article (PubMed ID: 30550791)
1. Organoid Modeling of the Tumor Immune Microenvironment.
Neal JT; Li X; Zhu J; Giangarra V; Grzeskowiak CL; Ju J; Liu IH; Chiou SH; Salahudeen AA; Smith AR; Deutsch BC; Liao L; Zemek AJ; Zhao F; Karlsson K; Schultz LM; Metzner TJ; Nadauld LD; Tseng YY; Alkhairy S; Oh C; Keskula P; Mendoza-Villanueva D; De La Vega FM; Kunz PL; Liao JC; Leppert JT; Sunwoo JB; Sabatti C; Boehm JS; Hahn WC; Zheng GXY; Davis MM; Kuo CJ
Cell; 2018 Dec; 175(7):1972-1988.e16. PubMed ID: 30550791
[TBL] [Abstract][Full Text] [Related]
2. Hedgehog transcriptional effector GLI mediates mTOR-Induced PD-L1 expression in gastric cancer organoids.
Koh V; Chakrabarti J; Torvund M; Steele N; Hawkins JA; Ito Y; Wang J; Helmrath MA; Merchant JL; Ahmed SA; Shabbir A; Yan So JB; Yong WP; Zavros Y
Cancer Lett; 2021 Oct; 518():59-71. PubMed ID: 34126195
[TBL] [Abstract][Full Text] [Related]
3. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
4. Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer.
Lal JC; Townsend MG; Mehta AK; Oliwa M; Miller E; Sotayo A; Cheney E; Mittendorf EA; Letai A; Guerriero JL
Breast Cancer Res; 2021 Aug; 23(1):83. PubMed ID: 34353349
[TBL] [Abstract][Full Text] [Related]
5. Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity.
Tanegashima T; Togashi Y; Azuma K; Kawahara A; Ideguchi K; Sugiyama D; Kinoshita F; Akiba J; Kashiwagi E; Takeuchi A; Irie T; Tatsugami K; Hoshino T; Eto M; Nishikawa H
Clin Cancer Res; 2019 Aug; 25(15):4808-4819. PubMed ID: 31076547
[TBL] [Abstract][Full Text] [Related]
6. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
[TBL] [Abstract][Full Text] [Related]
7. Mouse-Derived Gastric Organoid and Immune Cell Co-culture for the Study of the Tumor Microenvironment.
Chakrabarti J; Holokai L; Syu L; Steele N; Chang J; Dlugosz A; Zavros Y
Methods Mol Biol; 2018; 1817():157-168. PubMed ID: 29959712
[TBL] [Abstract][Full Text] [Related]
8. Organoid Models of Tumor Immunology.
Yuki K; Cheng N; Nakano M; Kuo CJ
Trends Immunol; 2020 Aug; 41(8):652-664. PubMed ID: 32654925
[TBL] [Abstract][Full Text] [Related]
9. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
10. Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy.
Yanik EL; Kaunitz GJ; Cottrell TR; Succaria F; McMiller TL; Ascierto ML; Esandrio J; Xu H; Ogurtsova A; Cornish T; Lipson EJ; Topalian SL; Engels EA; Taube JM
JAMA Oncol; 2017 Jul; 3(7):974-978. PubMed ID: 28334399
[TBL] [Abstract][Full Text] [Related]
11. Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts.
Woolaver RA; Wang X; Krinsky AL; Waschke BC; Chen SMY; Popolizio V; Nicklawsky AG; Gao D; Chen Z; Jimeno A; Wang XJ; Wang JH
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414263
[TBL] [Abstract][Full Text] [Related]
12. Micro-Engineered Organoid-on-a-Chip Based on Mesenchymal Stromal Cells to Predict Immunotherapy Responses of HCC Patients.
Zou Z; Lin Z; Wu C; Tan J; Zhang J; Peng Y; Zhang K; Li J; Wu M; Zhang Y
Adv Sci (Weinh); 2023 Sep; 10(27):e2302640. PubMed ID: 37485650
[TBL] [Abstract][Full Text] [Related]
13. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
14. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA
Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064
[TBL] [Abstract][Full Text] [Related]
15. Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer.
Sun F; Guo ZS; Gregory AD; Shapiro SD; Xiao G; Qu Z
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461344
[TBL] [Abstract][Full Text] [Related]
16. Chronic Adrenergic Stress Contributes to Metabolic Dysfunction and an Exhausted Phenotype in T Cells in the Tumor Microenvironment.
Qiao G; Chen M; Mohammadpour H; MacDonald CR; Bucsek MJ; Hylander BL; Barbi JJ; Repasky EA
Cancer Immunol Res; 2021 Jun; 9(6):651-664. PubMed ID: 33762351
[TBL] [Abstract][Full Text] [Related]
17. Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models.
Tsai S; McOlash L; Palen K; Johnson B; Duris C; Yang Q; Dwinell MB; Hunt B; Evans DB; Gershan J; James MA
BMC Cancer; 2018 Mar; 18(1):335. PubMed ID: 29587663
[TBL] [Abstract][Full Text] [Related]
18. Preclinical tumor organoid models in personalized cancer therapy: Not everyone fits the mold.
Hu LF; Yang X; Lan HR; Fang XL; Chen XY; Jin KT
Exp Cell Res; 2021 Nov; 408(2):112858. PubMed ID: 34600901
[TBL] [Abstract][Full Text] [Related]
19. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.
Zeng Y; Li B; Liang Y; Reeves PM; Qu X; Ran C; Liu Q; Callahan MV; Sluder AE; Gelfand JA; Chen H; Poznansky MC
FASEB J; 2019 May; 33(5):6596-6608. PubMed ID: 30802149
[TBL] [Abstract][Full Text] [Related]
20. Establishment of patient-derived organotypic tumor spheroid models for tumor microenvironment modeling.
Hong HK; Yun NH; Jeong YL; Park J; Doh J; Lee WY; Cho YB
Cancer Med; 2021 Aug; 10(16):5589-5598. PubMed ID: 34240815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
